Aota Y, Okamoto N, Morikawa S, Yoshida K
Department of Urology, National Nagoya Hospital, Japan.
Gan To Kagaku Ryoho. 1992 Jul;19(7):1015-8.
The efficacy and safety of Pirarubicin (THP), administered by intravesical instillation, have been studied in recurrent multiple superficial bladder cancer patients and patients who tested positive by urine cytology but lacked protuberant legions (CIS). The average age and range of the 19 patients (M 15, F4) studied were 63.3 (37-84). Twelve patients had protuberant, multiple cancer and 7 patients had CIS. Sixteen of the cases were recurrent disease. Twenty mg THP, delufed in 40 ml of 5% glucose solution were instilled for 2 hours once or twice a week. Each patients received 8 treatments. One week after the last treatment, the therapeutic result was evaluated on the bases of cystoscopy and urine cytology. Before and after administration, CBC and biochemical blood tests were run. Nine of the 12 patients (75%) with multiple recurrent tumor and all the 7 patients with CIS showed complete response. The total outcome for CR was 84.2% in this study. Intravesical instillation with THP did not cause any serious side effects.
已对复发的多发性浅表膀胱癌患者以及尿细胞学检查呈阳性但缺乏突出病变（原位癌）的患者进行了吡柔比星（THP）膀胱内灌注给药的疗效和安全性研究。所研究的19例患者（男性15例，女性4例）的平均年龄为63.3岁（37 - 84岁）。12例患者患有突出的多发性癌症，7例患者患有原位癌。其中16例为复发性疾病。将20毫克THP溶于40毫升5%葡萄糖溶液中，每周灌注1次或2次，持续2小时。每位患者接受8次治疗。最后一次治疗1周后，根据膀胱镜检查和尿细胞学检查评估治疗结果。给药前后进行血常规和血液生化检查。12例多发性复发性肿瘤患者中有9例（75%）以及所有7例原位癌患者均显示完全缓解。本研究中完全缓解的总有效率为84.2%。THP膀胱内灌注未引起任何严重副作用。
